REDD1 Is Involved in Amyloid β-Induced Synaptic Dysfunction and Memory Impairment
Authors:
Open Access
- 13 December 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9482
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by neurological dysfunction, including memory impairment, attributed to the accumulation of amyloid β (Aβ) in the brain. Although several studies reported possible mechanisms involved in Aβ pathology, much remains unknown. Previous findings suggested that a protein regulated in development and DNA damage response 1 (REDD1), a stress-coping regulator, is an Aβ-responsive gene involved in Aβ cytotoxicity. However, we still do not know how Aβ increases the level of REDD1 and whether REDD1 mediates Aβ-induced synaptic dysfunction. To elucidate this, we examined the effect of Aβ on REDD1-expression using acute hippocampal slices from mice, and the effect of REDD1 short hairpin RNA (shRNA) on Aβ-induced synaptic dysfunction. Lastly, we observed the effect of REDD1 shRNA on memory deficit in an AD-like mouse model. Through the experiments, we found that Aβ-incubated acute hippocampal slices showed increased REDD1 levels. Moreover, Aβ injection into the lateral ventricle increased REDD1 levels in the hippocampus. Anisomycin, but not actinomycin D, blocked Aβ-induced increase in REDD1 levels in the acute hippocampal slices, suggesting that Aβ may increase REDD1 translation rather than transcription. Aβ activated Fyn/ERK/S6 cascade, and inhibitors for Fyn/ERK/S6 or mGluR5 blocked Aβ-induced REDD1 upregulation. REDD1 inducer, a transcriptional activator, and Aβ blocked synaptic plasticity in the acute hippocampal slices. REDD1 inducer inhibited mTOR/Akt signaling. REDD1 shRNA blocked Aβ-induced synaptic deficits. REDD1 shRNA also blocked Aβ-induced memory deficits in passive-avoidance and object-recognition tests. Collectively, these results demonstrate that REDD1 participates in Aβ pathology and could be a target for AD therapy.Keywords
Funding Information
- National Research Foundation of Korea (2017R1C1B1003822, 2016R1A5A2007009)
- Korea Research Institute of Bioscience and Biotechnology (KGM5162021)
This publication has 51 references indexed in Scilit:
- Multifactorial Hypothesis and Multi-Targets for Alzheimer’s DiseaseJournal of Alzheimer’s Disease, 2018
- Diagnostic Accuracy of Memory Measures in Alzheimer’s Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-AnalysisNeuropsychology Review, 2017
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failuresAlzheimer's Research & Therapy, 2014
- Feedback Control of p53 Translation by REDD1 and mTORC1 Limits the p53-Dependent DNA Damage ResponseMolecular and Cellular Biology, 2011
- Animal models in the drug discovery pipeline for Alzheimer's diseaseBritish Journal of Pharmacology, 2011
- Glucocorticoid Elevation of Dexamethasone-induced Gene 2 (Dig2/RTP801/REDD1) Protein Mediates Autophagy in LymphocytesJournal of Biological Chemistry, 2011
- Elevated Corticosterone Associated with Food Deprivation Upregulates Expression in Rat Skeletal Muscle of the mTORC1 Repressor, REDD1The Journal of Nutrition, 2009
- Alterations in Memory Networks in Mild Cognitive Impairment and Alzheimer's Disease: An Independent Component AnalysisThe Journal of Neuroscience, 2006
- Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1Molecular and Cellular Biology, 2005
- Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complexGenes & Development, 2004